Eton Pharmaceuticals, Inc.
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $80.0M
- Net income
- -$4.6M
- Total assets
- $92.1M
- Market cap
- $797.9M
- Gross margin
- 53.5%
- Operating margin
- -1.1%
- Net margin
- -5.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $80.0M
- Cost of revenue
- $37.2M
- Gross profit
- $42.7M
- Operating expenses
- $43.6M
- Operating income
- -$844.0K
- Income tax
- $43.0K
- Net income
- -$4.6M
- EPS (basic)
- $-0.17
Balance sheet
- Total assets
- $92.1M
- Current assets
- $60.6M
- Total liabilities
- $66.0M
- Current liabilities
- $38.5M
- Shareholders’ equity
- $26.2M
Cash flow
- Operating cash flow
- $10.5M
- Investing cash flow
- -$333.0K
- Financing cash flow
- $815.0K
- Net cash flow
- $11.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $797.9M
- Shares outstanding
- 26.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 14, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $4.6M in FY2025.
- Revenue grew 266% from FY2021 to FY2025.
- Gross margin of 53.5%, net margin -5.8%.
- Trading 14% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Eton Pharmaceuticals, Inc..
Write a review
News about Eton Pharmaceuticals, Inc.
News & sentiment via Polygon.io
